Pharmaceuticals

Merck Strengthens Executive Board

DARMSTADT, Germany, September 19, 2014 /PRNewswire/ -- * Stefan Oschmann appointed Deputy CEO and Vice Chairman of the Executive Board * Belen Garijo appointed new member of the Executive Board * Changes effective from January 1, 2015 Merck today announced that the Board of Partners has pr...

2014-09-19 01:56 2171

Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine

SAN DIEGO, Sept. 17, 2014 /PRNewswire/ -- Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company (NYSE: LLY). Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all ...

2014-09-17 02:10 1972

First European Patients Enrolled in QT Vascular's ENDURE Trial

SINGAPORE, Sept. 16, 2014 /PRNewswire/ -- Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"), a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has enrolled ...

2014-09-16 01:46 1965

Alchem International Commits to Tropane Alkaloid APIs and Extends Production and Regulatory Support to Resolve Supply Gap

GENEVA, Sept. 15, 2014 /PRNewswire/ -- Following the decision by the principal European manufacturers to exit or end market development and regulatory support for the niche range of Tropane Alkaloid APIs (active pharmaceutical ingredients) - including Atropine, Atropine Sulfate, Tropine, Nortrop...

2014-09-15 09:00 1920

Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer

DARMSTADT, Germany, Sept. 12, 2014 /PRNewswire/ -- Not intended for UK-based media  Merck announced today that its biopharmaceutical division Merck Serono will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known a...

2014-09-12 22:47 1595

Kinex Completes Acquisition of QuaDPharma

NEW YORK, Sept. 9, 2014 /PRNewswire/ -- Kinex Pharmaceuticals Inc. today announced that it has completed the acquisition of QuaDPharma, LLC., aWestern New York based privately-held company specializing in pharmaceutical manufacturing, analytical and support services to the pharmaceutical and bio...

2014-09-09 23:40 1937

CPhI Korea 2014 Ends with a Great Success!

SEOUL, South Korea, Sept. 8, 2014 /PRNewswire/ -- CPhI Korea 2014, organized by the leading events organiser UBM and Korea Pharmaceutical exhibition, was held at Coex from 2nd to 3rd of September. In the welcome luncheon on 2nd of September, Joung Kyu Lee, chairman of Korea Pharmaceutical Trader...

2014-09-08 20:55 1408

Frost & Sullivan Recognizes DSM Biomedical's Outstanding Growth as a 'Total Solutions' Provider in the Medical Device Coatings Market

MOUNTAIN VIEW, Calif., Sept. 8, 2014 /PRNewswire/ -- Based on its recent analysis of the medical device coatings market, Frost & Sullivan recognizes DSM Biomedical with the 2014 North America Frost & Sullivan Award for Growth Excellence Leadership. DSM Biomedical is a total solutions provider tha...

2014-09-08 20:00 1243

New Platforms Enhance AMRI's Discovery Biology Offerings

ALBANY, N.Y., Sept. 4, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that it has expanded into the protein market, with an initial focus on protein expression and purification. The global revenue of the total proteomics market is anticipated to grow at a compound annual growth rate of ...

2014-09-04 20:00 1052

First Tele-health Programme for Heart Failure Patients in Singapore Enables Patients to Better Manage their Health and Reduce Hospitalisation

SINGAPORE, Sept. 4, 2014 /PRNewswire/ -- The Eastern Health Alliance (EH Alliance) and Changi General Hospital (CGH) have partnered Philips Healthcare (Philips) to pilotSingapore's first tele-health programme for heart failure patients inSingapore. The innovative programme integrates three key...

2014-09-04 17:14 1769

New Data Presented at WCCS Confirm High Long-term Efficacy of Picato® in Patients with Actinic Keratosis

BALLERUP, Denmark, Sept. 4, 2014 /PRNewswire/ -- Not for US media The digital press release with multimedia content can be accessed here: http://www.multivu.com/players/uk/7276254-WCCS-Picato-actinickeratosis/ New data f...

2014-09-04 14:00 1443

Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in Children with PKU Below 4 Years of Age

DARMSTADT, Germany, Sept. 3, 2014 /PRNewswire/ -- Not intended for UK based media * Detailed 26-week results of SPARK study presented at SSIEM Annual Symposium  * Phenylalanine tolerance significantly increased in children with PKU below 4 years of age, previously shown to be responsive to Ku...

2014-09-03 21:33 1424

Shanghai Pharmaceuticals Achieves Double-Digit Growth of Revenue and Profit for 1H2014

HONG KONG, Aug. 30, 2014 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co., Ltd.("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both ph...

2014-08-30 00:07 2090

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

OSAKA, Japan, Aug. 29, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of data from a 10-year epidemiology study to regulatory authorities includingthe United States (U.S.) Food and Drug Adminis...

2014-08-29 01:16 1869

CAIDE Looks into the Future: New App from Merz Pharmaceuticals Assesses the Risk of Getting Dementia Within the Next 20 Years

FRANKFURT AM MAIN, Germany, Aug. 29, 2014 /PRNewswire/ -- The CAIDE Dementia Risk App from Merz Pharmaceuticals is available free of charge for people from 40 to 65 to calculate their individual risk for getting dementia within the next two decades. Using a traffic light color scheme, the App can...

2014-08-29 00:24 1657

CPhI & P-MEC China 2014 Event Achieved its Grand Closing

SHANGHAI, Aug. 26, 2014 /PRNewswire/ -- CPhI, ICSE & BioPh China 2014 and P-MEC, InnoPack & LABWorld China 2014, held on 26th -28th of June hosted by UBM Live and CCCMHPIE and co-organized by UBM Sinoexpo, achieved its successful close at Shanghai New International Expo Centre.

2014-08-26 09:00 1733

ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

LONDON, Aug. 23, 2014 /PRNewswire/ -- ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is ViiV Healthcare's first dolutegravir-based ...

2014-08-23 04:17 3687

Amerigen Pharmaceuticals Ltd. Announces that its Chinese Subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has Received Chinese FDA (CFDA) Approval and has Subsequently Launched its Generic Mecobalamin 0.5 mg Tablets into the China Domestic Market

LYNDHURST, N.J., Aug. 20, 2014 /PRNewswire/ -- Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into theChina domestic market...

2014-08-20 21:37 2084

Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study

REDWOOD CITY, California, Aug. 15, 2014  /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira® in ...

2014-08-15 06:33 2336

Mundipharma Announces Principal Partner Sponsorship for Singapore's National Day Parade 2014

SINGAPORE, Aug. 7, 2014 /PRNewswire/ -- Mundipharma, one of the fastest growing pharmaceutical companies in the region, announced today its status as principal partner of this year's National Day Parade (NDP)  -- the first time ever for a pharmaceutical company to hold this position. In celebrati...

2014-08-07 09:00 2331